Trial Profile
A Phase 1b, Open-label Study to Evaluate the PK, Safety and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 14 Sep 2022 Status changed from active, no longer recruiting to completed.
- 24 Feb 2022 Planned End Date changed from 1 Feb 2023 to 1 Oct 2022.
- 24 Feb 2022 Planned primary completion date changed from 1 Jan 2023 to 1 Sep 2022.